- Global Blood Therapeutics reported a strong Q4/2020 despite COVID-19 headwinds. The company's flagship product, Oxbryta, is off to a great start with a solid base moving into 2021.
- Shortly after Oxbryta's approval, I decided to book some profits and sock drawer the rest of the position. The recent sell-off has enticed me to change my strategy.
- Global Blood Therapeutics has an impressive pipeline that could generate long-term growth and make the company the undisputed leader in sickle cell disease care.
- I discuss some of my leading downside risks and reveal my new GBT strategy.
For further details see:
Global Blood Therapeutics: Sell-Off Alters My Investment Strategy